ArticleOncotarget2017
Fluorescence contrast-enhanced proliferative lesion imaging by enema administration of indocyanine green in a rat model of colon carcinogenesis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Fluorescence imaging for real-time detection of breast cancer tumors using IV injection of indocyanine green with non-conventional imaging: a systematic review of preclinical and clinical studies of perioperative imaging technologies.Breast cancer research and treatment · 2024Pooled it
- Real-timeFrontiers in oncology · 2026Article
- Mechanisms of delayed indocyanine green fluorescence and applications to clinical disease processes.Surgery · 2024Review
- Near infrared conjugated polymer nanoparticles (CPN™) for tracking cells using fluorescence and optoacoustic imaging.Nanoscale advances · 2023Article
- Substituent directed cellular imaging in the 800-850 nm range with BFRSC advances · 2023Article
- Article
- Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment.Molecular biomedicine · 2022Article
- Photoacoustic nanodroplets for oxygen enhanced photodynamic therapy of cancer.Photoacoustics · 2022Article
- Progresses in Fluorescence Imaging Guidance for Bone and Soft Tissue Sarcoma Surgery.Frontiers in oncology · 2022Review
- Digital dynamic discrimination of primary colorectal cancer using systemic indocyanine green with near-infrared endoscopy.Scientific reports · 2021Article
- Fluorescence tumor imaging by i.v. administered indocyanine green in a mouse model of colitis-associated colon cancer.Cancer science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fluorescent contrast agent indocyanine green (ICG) is approved by the Food and Drug Administration for clinical applications. We previously reported that cultured human colon tumor cells preferentially take up ICG by endocytic activity in association with disruption of their tight junctions. The present study explored ICG availability in fluorescence imaging of the colon to identify proliferative lesions during colonoscopy. The cellular uptake of ICG in cultured rat colon tumor cells was examined using live-cell imaging. Colon lesions in rats administered an ICG-containing enema were further assessed in rats with azoxymethane-induced colon carcinogenesis, using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.